Business
-
Days after announcing that the FDA has accepted its NDA resubmission for Gimoti metoclopramide nasal spray for the treatment of diabetic gastroparesis, Evoke Pharma said that the company has cancelled a previously announced commercialization deal… Read more . . .
-
AstraZeneca has announced a commitment to launching a “next-generation” MDI with minimal global warming potential (GWP) propellants by 2025 as part of its $1 billion “Ambition Zero Carbon” program. The new program, which was announced… Read more . . .
-
Virpax Pharmaceuticals announced that it has acquired exclusive global rights from Nanomerics Ltd. for the use of molecular envelope technology (MET) for delivery of an intranasal formulation of enkephalin for the treatment of PTSD. The company… Read more . . .
-
Altavant Sciences has announced its acquisition of Onspira Therapeutics, which apparently had a single candidate in its pipeline: OSP-101, an inhaled interleukin-1 receptor antagonist. In August 2018, the FDA granted Orphan Drug designation to OSP-101… Read more . . .
-
AI Therapeutics (formerly LAM Therapeutics) said that it is seeking a partner to advance its LAM-001 inhaled rapamycin into Phase 3 trials for the treatment of lymphangioleiomyomatosis (LAM disease) and into Phase 2 for the… Read more . . .
-
According to MannKind Corporation, Brazil’s Drug Market Regulation Chamber (CMED) has approved the proposed pricing for Afrezza inhaled insulin, and the Afrezza DPI is set to launch in Brazil within the next week. The Brazilian Health… Read more . . .
-
Canadian CRO Impopharma, which specializes in OINDP analysis and development, has been acquired by Rubicon Research, Rubicon said. Impopharma’s Concord, ON facility will become Rubicon’s Nasal and Pulmonary Center of Excellence. Impopharma’s services included testing… Read more . . .
-
Two months after announcing the appointment of Nocion Therapeutics CEO Rick Batycky to its board, Pulmatrix has announced a deal with Nocion to look at the use of Pulmatrix’s iSPERSE particle engineering technology for development… Read more . . .
-
ATAI Life Sciences has announced a deal with US-based Neuronasal Inc. for development of intranasal N-acetylcysteine (NAC) for the treatment of mild traumatic brain injury (mTBI, or concussion). ATAI said that it expects initiation of… Read more . . .
-
According to Pulmatrix, the Lung Cancer Initiative at Johnson & Johnson will pay $7.2 million up front plus a $2 million milestone payment for an option “to access a portfolio of narrow spectrum kinase inhibitors intended for development… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden